CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma

Clinical Lymphoma

Volumn 1, Issue 1, 2000, Pages 57-61

  Warren, Thomas L ^a   Dahle, Christopher E ^a   Weiner, George J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity; Immunostimulatory DNA; Monoclonal antibody; NK cell; Th 1 response

Indexed keywords

CANCER ANTIBODY; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; C3H MOUSE; CANCER TRANSPLANTATION; CPG ISLAND; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; IMMUNOLOGY; MORTALITY; MOUSE; NATURAL KILLER CELL; SURVIVAL RATE; TH1 CELL; TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CPG ISLANDS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES; SURVIVAL RATE; TH1 CELLS; TIME FACTORS;

EID: 0034208490     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.005     Document Type: Article

References (34)

1. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-549.
2. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158:3635-3639.
3. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and Interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879-2883.
4. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157:1840-1845.
5. Redford TW, Yi AK, Ward CT, et al. Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 1998; 161:3930-3935.
6. Bohle B, Jahn-Schmid B, Maurer D, et al. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999; 29:2344-2353.
7. Sparwasser T, Miethke T, Lipford G, et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997;27:1671-1679.
8. Yamamoto S, Yamamoto T, Shimada T, et al. DNA from bacteria, but not vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microl Immunol 1992; 36:983.
9. Spanwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28:2045-2054.
10. Messina JP, Gilkeson GS, Pisetsky DS. Simulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991; 147:1759-1764.
11. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157:2116-2122.
12. Yamamoto S, Kuramoto E, Shimada S, et al. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988; 79:866-873.
13. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 16:9305-9310.
14. Carpentier AF, Chen L, Maltonti F, et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59:5429-5432.
15. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160:870-876.
16. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Nat Acad Sci USA 1997; 94: 10833-10837.
17. Lipford GB, Sparwasser T, Bauer M, et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 1997; 27:3420-3426.
18. Roman M, Martinorozco E, Goodman S. et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-854.
19. Chu RS, Targoni OS, Krieg AM, et al. CpG Oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-1631.
20. Liu HM, Newbrough SE, Bhatia SK, et al. Immunostimulatory CpG oligodeoxy-nucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92:3730-3736.
21. Wooldridge JE, Ballas Z, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89:2994-2998.
22. Campbell MJ, Esserman L, Byars NE, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145:1029-1036.
23. Maloney DG, Kaminski MS, Burowski D, et al. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985; 4:191-209.
24. Weiner GJ, Kaminski MS. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. J Immunol 1989; 142:343-351.
25. Weiner GJ, Kaminski MS. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. J Immunol 1990; 144:2436-2445.
26. Berinstein N, Levy R.Treatment of a murine B cell lymphoma with monodonal antibodies and IL-2. J Immunol 1987; 139:971-976.
27. Starnes CO, Carroll WL, Campbell MJ, et al. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol 1988; 141:333-339.
28. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977; 7:413-417.
29. Eshhar Z, Blatt C, Bergman Y, et al. Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol 1979; 122:2430-2434.
30. Kaminski MS, Kitamura K, Maloney DG, et al. Importance of antibody isotype in monodonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986; 136: 1123-1130.
31. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci 1893; 105: 487-511.
32. Coley WB. Treatment of inoperable malignant tumors with the toxins of erysipelas and the bacillus Prodigiosus. Am J Med Sci 1894; 108:183-212.
33. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmocol Ther 1994; 64:529-564.
34. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164:1617-1624.